Corporate & Investor Presentation
Big data analysis drives insights for treatment of central sleep apnea
Patients with treatment-emergent central sleep apnea (CSA) are 2x more
likely to terminate therapy
• Opportunity to rethink conventional therapeutic options
Minimize risk of therapy termination through early diagnosis
• Regularly monitor patients to support adherence to treatment
100
50
Analysis of ~200k CSA patients
22% increase in adherence
CMS adherence on CPAP
prior to switching
62.7%
CMS adherence
after switching to ASV
76.6%
Switching from therapy
CPAP to ASV improved
relative adherence by
22%
Patients who switched
from CPAP to ASV had
fewer apneas and
hyponeas during sleep
452022 ResMed | Corporate & Investor Presentation - updated 28APR22
HAH
CHEST
Journal
ResMedView entire presentation